Obstructive Lung Disease
12 cases on [genuine one-line description of what this topic's real clinical territory covers] — choose a case below to open its full multi-voice debate.
A patient whose eosinophils and exhaled nitric oxide both sit in a real but unremarkable middle zone, with no trial that has ever compared the three biologic mechanisms actually available to her.
A biologic-naive patient eligible for either of two drugs by every standard criterion, with the decision actually turning on how CHEST's own algorithm reads his exacerbation history.
A patient whose eosinophil count sits above the mepolizumab threshold and below the dupilumab one, on evidence that is real for the drug he qualifies for and stronger for the one he does not.
An adherence problem that a twice-yearly biologic would genuinely solve, in a patient whose one hospitalization last year is exactly the kind of event a six-month monitoring gap could miss early.
A steroid-dependent patient whose biologic has clearly not done its job, with CHEST's own algorithm and a cautionary switch trial pulling the next decision in two different directions.
A patient who meets essentially every published criterion for stopping a biologic, in a field that openly admits no standardized remission definition actually exists.
A patient whose eosinophils and exhaled nitric oxide are both unremarkable, leaving exactly one biologic mechanism he is eligible for and real uncertainty about how well it will actually work at his numbers.
A patient who clears GOLD 2026's lowered eosinophil bar for escalating to triple therapy, with a real pneumonia history that makes the decision feel closer than the number alone suggests.
A patient who fits the frequent-exacerbator profile chronic azithromycin was built for, complicated by a baseline QTc that sits close enough to the drug's own warning threshold to change how the decision gets made, not whether it does.
A patient who matches every enrichment criterion the roflumilast evidence was built around, whose already-thin build makes the drug's own best-documented side effect a genuinely different calculation for her.
A patient with real COPD and real asthma both present in the same lungs, whose eosinophilia and reversibility argue for treating the asthma component directly rather than defaulting to whichever label came first.
A patient whose asthma and nasal polyps are both driven by the same disease, choosing between a therapy that has repeatedly failed to hold and two newer options with no trial ever comparing them directly.